SCHEMBL5887217

SCHEMBL5887217

COc1ccc(C2=C(C)C(c3ccc(C)cc3)=CC[CH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.47
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 3/20 0.41
ALOX5 P09917 2/20 0.40
RELA Q04206 1/20 0.40
BACE1 P56817 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GSK3B P49841 1/20 0.37
EGFR P00533 1/20 0.36
KDR P35968 1/20 0.36
ALKBH3 Q96Q83 1/20 0.36
PTGS2 P35354 1/20 0.36
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
MAPK1 P28482 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009121 0.88 ALDH1A1 (0.33) ACHEKMT2AMAPTSMN1; SMN2MEN1
SCHEMBL5887317 0.88 ALOX5 (0.39) NPC1RAB9AKMT2AALOX5BACE1
SCHEMBL5887229 0.86 ACHE (0.46) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887293 0.85 LTA4H (0.50) NPC1RAB9AKMT2ABACE1MAPT
SCHEMBL5887070 0.85 ACHE (0.44) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887645 0.81 RAD51 (0.37) MAPTSMN1; SMN2EGFRHPGDCLK4
SCHEMBL5887283 0.79 BACE1 (0.42) NPC1RAB9AKMT2ABACE1MAPT
SCHEMBL4007569 0.79 ACHE (0.33) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887073 0.78 ACHE (0.47) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887271 0.78 ACHE (0.47) ACHENPC1RAB9AKMT2AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ACHE 915/4885NPC1 1831/4885RAB9A 1054/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ACHE 3650/4885NPC1 2930/4885RAB9A 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.